Repros Therapeutics Inc (RPRX.OQ)
Mon, Apr 10 2017
* Company holds meeting with FDA to discuss oral Proellex® in the treatment of uterine fibroids
* Repros names Larry Dillaha, M.D., its permanent president and ceo
* Repros Therapeutics Inc reports fourth quarter and year end 2016 financial results
* Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately Source text for Eikon: Further company coverage:
* Repros Therapeutics In Reports third quarter 2016 financial results
- Neurocrine Biosciences Building To A Big 2017
- Biotech Forum Daily Digest: Another Big Gain For Biotech; Some Small Caps On The Move; Relypsa Continues To Roll
- Lipocine Vs. Antares: Who Wins?
- 2016 Outlook: Biotech Bear Market Continues
- Premarket Biotech Digest: Geron On The Move, Repros Tumbles, GlobeImmune Rumors
- Is It All Over For Repros Therapeutics?